Aprotinin is a potent multi-target drug for the combination therapy of moderate COVID-19 cases

ПРЕПРИНТ

Эта статья является препринтом и не была отрецензирована.
О результатах, изложенных в препринтах, не следует сообщать в СМИ как о проверенной информации.

Ivashchenko A. A.,

Azarova V. N.,

Egorova A. N.,

Karapetian R. N.,

Kravchenko D. V.,

Krivonos N. V.,

Loginov V. G.,

Poyarkov S. V.,

Merkulova E. A.,

Rosinkova O. S.,

Savchuk N. P.,

Topr M. A.,

Simakina E. N.,

Yakubova E. V.,

Ivachtchenko A. V.

2020-11-17

https://doi.org/10.21055/preprints-3111905

Objectives. COVID-19 is a contagious multisystem inflammatory disease caused by a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We have studied the efficacy of Aprotinin (nonspeciﬁc serine proteases inhibitor) and Avifavir or Hydroxychloroquine (HCQ) combinations for the therapy of COVID-19. Methods. Three prospective single-center (cohorts 1 – 3) studies included participants with moderate COVID-19-related pneumonia, laboratory-confirmed SARS-CoV-2 and admitted to the hospitals. Patients received combinations of intravenous (IV) Aprotinin (1,000,000 KIU daily, 3 days) and HCQ (cohort 1), inhalation (inh) treatment with Aprotinin (625 KIU 4 times per day, 5 days) and HCQ (cohort 2) or IV Aprotinin (1,000,000 KIU daily for 5 days) and Avifavir (cohort 3). Results. In the cohorts 1 – 3, the combination therapy showed 100% efficacy in preventing the transfer of patients (n = 30) to the intensive care unit (ICU). The effect of combination therapy in the cohort 3 was the most prominent and the median time to SARS-CoV-2 elimination was 3.5 days (IQR 3.0 – 4.0), normalization of CRP concentration was 3.5 days (IQR 3 – 5), of D-dimer concentration - 5 days (IQR 4 – 5); body temperature - 1 day (IQR 1 – 3), improvement in clinical status or discharge from the hospital - 5 days (IQR 5 – 5), and improvement in lung lesions of patients on 14 day - 100%. Conclusions. The administration of Aprotinin combinations prevented the transfer of moderate COVID-19 patients to the ICU for mechanical ventilation (ALV) or non-invasive ventilation (NIV) and by shortening of their hospital stay.

Ссылка для цитирования:

Ivashchenko A. A., Azarova V. N., Egorova A. N., Karapetian R. N., Kravchenko D. V., Krivonos N. V., Loginov V. G., Poyarkov S. V., Merkulova E. A., Rosinkova O. S., Savchuk N. P., Topr M. A., Simakina E. N., Yakubova E. V., Ivachtchenko A. V. 2020. Aprotinin is a potent multi-target drug for the combination therapy of moderate COVID-19 cases. COVID19-PREPRINTS.MICROBE.RU. https://doi.org/10.21055/preprints-3111905

Список литературы

1. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. November 1, 2020.

2. https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6/.

3. Zheng KI, Feng G, Liu W-Y, et al. Extrapulmonary complications of COVID‐19: A multisystem disease? J Med Virol 2020 Jul 22: 10.1002/jmv.26294, doi: 10.1002/jmv.26294.

4. Hayıroğlu MI, Çınar T, Tekkeşin AI. Fibrinogen and D-dimer variances and anticoagulation recommendations in Covid-19: current literature review. Rev Assoc Med Bras 2020, 66(6). https://doi.org/10.1590/1806-9282.66.6.842.

5. Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020, 191, 145-147. doi: 0.1016/j.thromres.2020.04.13

6. Cui S, Chen S, Li X, et al. Wang. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost 2020, 18(6), 1421-1424. doi: 10.1111/jth.14830.

7. Ivashchenko AA, Dmitriev KA, Vostokova NV et al. AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial. Clin Infect Dis 2020 Aug 9: ciaa1176, https://doi.org/10.1093/cid/ciaa1176.

8. Wang G, Wu C, Zhang O, et al. C-Reactive Protein Level May Predict the Risk of COVID19 Aggravation. OFID 2020, 7(5), ofaa153, https://doi.org/10.1093/ofid/ofaa153.

9. Tu Y-F, Chien C-H, Yarmishun AA, et al. A Review of SARS-CoV-2 and the Ongoing Clinical Trials. Int J Mol Sci 2020, 21(7), 2657. https://doi.org/10.3390/ijms21072657.

10. Scavone C, Brusco S, Bertini M, et al. Current pharmacological treatments for COVID‐19: What's next? Br J Pharmacol 2020 Apr 24; 10.1111/bph.15072. doi: 10.1111/bph.15072.

11. Scheule AM, Beierlein W, Wendel HP, et al. Aprotinin in fibrin tissue adhesives induces specific antibody response and increases antibody response of high-dose intravenous application. J Thorac Cardiovasc Surg 1999, 118(2), 348-353.

12. Ascenzi P, Bocedi A, Bolognesi M. The bovine basic pancreatic trypsin inhibitor (Kunitz inhibitor): a milestone protein. Curr Protein Pept Sci 2003 Jun; 4(3), 231–251.

13. Engles L. Review and application of serine protease inhibition in coronary artery bypass graft surgery Am J Health Syst Pharm 2005 Sep 15; 62(18 Suppl 4), S9–14.

14. Solun B, Shoenfeld Y. Inhibition of metalloproteinases in therapy for severe lung injury due to COVID-19. Med Drug Discov 2020 Sep; 7, 100052.

15. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020, 181(2), 271-280.e8. doi: 10.1016/j.cell.2020.02.052.

16. Bojkova D, Bechtel M, McLaughlin K-M, et al. Aprotinin Inhibitors SARS-CoV-2 Replication. Cells 2020, 9(11), 2377; https://doi.org/10.3390/cells9112377.

17. Science News. Cancer's next magic bullet may be magic shotgun. University of California - San Francisco, June 15, 2012. https://www.sciencedaily.com/releases/2012/06/120615141716.htm.

18. Ivashchenko AA, Svistunov AA, Khorobryh TV, et al. Aprotinin - a New Drug Candidate for The Prevention of SARS-CoV-2 (COVID-19). COVID19-PREPRINTS 2020-09-13. https://covid19-preprints.microbe.ru/files/140.

19. Ivashchenko AA, Svistunov AA, Khorobryh TV, et al. Aprotinin ‐ a new multi-target drug candidate or "magic shotgun" for the therapy of COVID‐19. COVID19-PREPRINTS 2020-10-03. https://covid19-preprints.microbe.ru/files/148.

20. WHO R&D Blueprint novel Coronavirus COVID-19 Therapeutic Trial Synopsis. February 18, 2020, Geneva, Switzerland.

21. Minister of Health of the Russian Federation. Interim guidelines prevention, diagnostics and treatment of new coronavirus infection (2019-nCoV) Version 7 (2020.06.03) (Russian language). https://static-0.rosminzdrav.ru/system/attachments/attaches/000/050/584/original/03062020_%D0%9CR_COVID-19_v7.pdf.

22. Huet T, Beaussier H, Voisin O, et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheuvatology 2020, 2(7), e393-e400. www.thelancet.com/rheumatology.

23. Thorlund K, Dron L, Park J, et al. A real-time dashboard of clinical trials for COVID-19. Lancet Digital Health 2020, 2(6), e286-e287. https://doi.org/10.1016/S2589-7500(20)30086-8.

24. FDA approves first treatment for COVID-19. FDA news release October 22, 2020. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19.

25. Khrennikov I. Russian Health Ministry Approves Anti-Coronavirus Drug Avifavir. Bloomberg.com 2020. https://www.bloomberg.com/news/articles/2020-05-31/russian-health-ministry-approves-anti-coronavirus-drug-avifavir.

ПРЕПРИНТ

ИНФОРМАЦИЯ О ПРЕПРИНТЕ